Gastrointestinal Stromal Tumour Treatment in Mumbai

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, arising predominantly in the stomach and small intestine. Although still relatively uncommon compared with epithelial gastrointestinal cancers, they are clinically important because of their distinctive biology and the availability of highly effective targeted drugs. Early identification and prompt specialist management improve outcomes and expand treatment choices. 

GISTs originate from or resemble the interstitial cells of Cajal, the pacemaker cells that regulate gut motility and usually carry activating mutations in KIT or PDGFRA genes; these molecular features both confirm diagnosis and direct therapy. Risk factors include increasing age and certain hereditary syndromes, though most cases are sporadic.

Types of GISTs

Low-risk GISTs

Some small GISTs behave indolently with minimal mitotic activity and very low risk of spread. These are often found incidentally and may be managed conservatively in selected circumstances.

Cancerous (malignant) GISTs

Tumours with higher mitotic rates, larger size, and specific high-risk locations or molecular features are considered malignant because of their capacity to recur locally or metastasise (most commonly to the liver and peritoneum). Staging and molecular testing guide the classification and treatment approach. 

Gastrointestinal Stromal Tumour Symptoms

Clinical presentation varies, but common symptoms include:

• Abdominal pain or discomfort: Often dull or cramping in nature, which may worsen with tumour growth or local pressure on surrounding structures.
  
  
• Gastrointestinal bleeding presenting as melaena or anaemia: Bleeding into the gastrointestinal tract can cause black, tarry stools or gradual blood loss leading to fatigue and pallor.
  
  
• Early satiety, abdominal fullness or palpable mass: Tumour presence can reduce stomach capacity or displace nearby organs, making the patient feel full after small meals.
  
  
• Obstructive symptoms if the tumour narrows the bowel lumen: This can lead to nausea, vomiting, bloating, and inability to pass stools or flatus.
  
  

Impact of Tumour Location and Size on Symptoms

The severity and type of symptoms depend greatly on the location and size of the GIST. 

• Gastric GISTs: More likely to cause upper abdominal discomfort or bleeding.
• Small intestine GISTs: Often lead to blockage-related symptoms such as nausea or vomiting.
• Smaller tumours: May remain symptom-free and are sometimes found incidentally during routine imaging or endoscopy.

Gastrointestinal Stromal Tumour Causes

GISTs arise when somatic mutations activate receptor tyrosine kinases (commonly KIT; less often PDGFRA), driving uncontrolled cellular proliferation. A minority of tumours are associated with inherited syndromes (for example, neurofibromatosis type 1 or succinate dehydrogenase deficiencies). The molecular subtype influences both natural history and response to specific inhibitors. 

Stages of Gastrointestinal Stromal Tumours

The stage of a gastrointestinal stromal tumour (GIST) describes how far the disease has progressed and is important for selecting the most appropriate treatment and estimating prognosis. For a localised disease, clinicians employ risk assessment based on size, location, mitotic rate, and tumour rupture to predict the risk of recurrence and decide on treatment. 

Stage progression in GIST ranges from localised disease confined to its site of origin to locally advanced tumours invading nearby tissues and metastatic disease spreading to distant organs. Staging guides treatment choices and helps predict prognosis and follow-up needs.

Diagnosing Gastrointestinal Stromal Tumours

Accurate diagnosis combines endoscopic evaluation, advanced imaging, and tissue sampling, ensuring precise characterisation of the tumour. Key diagnostic methods include:

• Endoscopy: Uses a flexible camera to inspect the gastrointestinal tract, detect abnormal growths or ulcerations, and determine the need for further targeted investigations.
  
  
• Endoscopic Ultrasound (EUS): Combines endoscopy with high-resolution ultrasound to visualise tumour depth, surrounding structures, and enables fine-needle aspiration for sample collection.
  
  
• Imaging Studies: Contrast-enhanced CT Scan is standard for mapping tumour size, location, and spread; MRI or PET may be used for specific clinical scenarios.
  
  
• Biopsy: Obtains tissue samples for microscopic and immunohistochemical analysis, confirming diagnosis and guiding targeted therapy through the detection of specific protein markers.

Gastrointestinal Stromal Tumour Treatment Options

Treatment for gastrointestinal stromal tumours is tailored to the tumour’s stage, location, and genetic profile, with options ranging from surgery to targeted systemic therapies for advanced disease.

• Surgery: Primary treatment for localised GISTs, aiming for complete tumour removal with negative margins while preserving organ function; may be combined with pre- or post-operative targeted therapy.
  
  
• Targeted Therapy: Uses tyrosine kinase inhibitors, such as imatinib, to block specific genetic mutations driving tumour growth; effective in advanced, recurrent, or high-risk GISTs after surgery.
  
  
• Radiation Therapy: Rarely used as a primary treatment; may help control symptoms like pain or bleeding in advanced disease when surgery is not feasible.
  
  
• Chemotherapy: Conventional cytotoxic drugs have minimal effect on GISTs; generally reserved for research settings or cases resistant to targeted therapies.

Why Choose Nanavati Max Hospital for Treatment

Selecting a high-volume centre with an experienced MDT is fundamental. Nanavati Max Hospital in Mumbai provides a dedicated gastrointestinal cancer programme, access to surgical oncology, medical oncology for TKI management, advanced imaging and pathology services, and supportive care. 

When choosing a facility or surgeon, consider institutional experience with GIST, availability of molecular testing, access to targeted agents and clinical trials, and structured follow-up pathways. 

Recovery and Rehabilitation

Post-operative recovery depends on the extent of resection and the patient’s baseline fitness. Early mobilisation, adequate pain control, nutritional optimisation, and physiotherapy are key elements of rehabilitation. 

Potential complications like bleeding, infection, anastomotic leak, or ileus are managed promptly by the surgical team; targeted therapy may cause side-effects (eg, oedema, fatigue, cytopenias) that require specialist input and dose adjustments. Clear discharge instructions and early outpatient review minimise avoidable problems. 

Long-term Follow-up and Surveillance

Long-term surveillance typically involves periodic clinical assessment and cross-sectional imaging (CT or MRI) at intervals determined by initial risk and treatment. Lifelong follow-up is often recommended for those at higher risk of recurrence. 

Surveillance enables early detection of relapse, timely institution of systemic therapy, and coordination of supportive services. Ongoing communication between the patient and their oncology team in Mumbai ensures prompt management of late effects and disease progression. 

Related Blogs

Stomach Cancer - Types, Diagnosis & Other Treatment

What is It & Symptoms of Gastrointestinal Disorders?

Gastrointestinal Diseases: Common Issues in Women & Its

Common Digestive Disorders That Can Affect Anyone

Intestinal Obstruction: Factors, Types and Treatment

Frequently Asked Questions

1. Is GIST surgery always necessary?

Small tumours with very low-risk features may be observed; operative treatment is recommended for lesions with significant risk of progression or symptomatic disease. Decisions are made case by case.

2. Are minimally invasive surgical options available for GIST treatment?

Yes. Selected GISTs, smaller than 5 cm, can be operated with minimally invasive robot assisted surgery approach. Minimally invasive options are not preferred for tumours exceeding 10 cm due to the associated risks. 

3. How can I schedule an appointment for GIST evaluation?

Contact the hospital’s gastro-oncology or cancer centre through the online booking portal, hospital switchboard, or by phone to request a specialist referral.

4. Are there non-surgical treatments available for GIST?

Targeted oral medications (tyrosine kinase inhibitors) and palliative radiotherapy are non-surgical options used according to disease stage and molecular profile.

5. How much does GIST surgery typically cost?

Costs vary with procedure type, length of stay and investigations. For an accurate estimate, obtain a personalised quotation from the hospital billing office after an initial clinic review.

6. What should I expect during recovery after GIST treatment?

Expect a gradual return to activity with wound care, dietary guidance, and scheduled outpatient checks; some patients require temporary dietary modification or short-term analgesia.

7. What specialised services does Nanavati Max Hospital offer for GIST diagnosis?

The centre provides multidisciplinary review, contrast imaging, endoscopic and EUS procedures, expert histopathology with immunohistochemistry and molecular testing, and oncology clinics.

8. Can I request a second opinion at Nanavati Max Hospital?

Yes, the hospital accepts second-opinion requests; bring all prior records, imaging and pathology slides/reports for review.

9. Can I expect a personalised treatment plan at Nanavati Max Hospital?

Patients are evaluated by an MDT and receive a treatment pathway tailored to tumour stage, mutational status and personal circumstances.

10. Can GIST return after surgery?

Yes, recurrence can occur; structured surveillance and, when indicated, adjuvant therapy aim to reduce that risk.